You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Healthcare professionals can inject the regimen, containing Perjeta, Herceptin, and hyaluronidase, in patients' homes after intravenous chemotherapy.
The study showed that patients with targetable genomic markers, especially HER2 alterations, responded well to chemotherapy-free treatments.
Benefit was seen for patients with high TMB on Keytruda, with ERBB2 amplifications on Perjeta and Herceptin, and with BRAF mutations on Cotellic plus Zelboraf.
Investigators provided updated evidence that that the combined treatment prevents more women from relapsing, especially higher-risk node-positive patients.
A collection of biomarker- and genomic testing-driven precision oncology research presented at the European Society of Medical Oncology Congress.